Curis, Inc. · NASDAQ:CRIS
Curis — Investor Presentation (November 2024)
39 slides from Curis's investor presentation, November 2024
Slide 1: Corporate Presentation
Corporate Presentation November 2024
Slide 2: Cautionary note regarding forward looking statements and disclaimers
Cautionary note regarding forward looking statements and disclaimers This presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “expect(s),” “beli
Slide 3: Emavusertib is a potential first-to-market IRAK4 inhibitor
Emavusertib is a potential first-to-market IRAK4 inhibitor • Being evaluated in Phase 1/2 clinical Acceptable safety profile in studies in NHL, AML, and Solid Tumors monotherapy & combination • Broad opportunity in NHL, AML and Solid Tumors Demonstrated synergy • Cash runway into mid-2025 with BTKi,
Slide 4: Broad Market Opportunity in NHL, AML, and Solid Tumors
Broad Market Opportunity in NHL, AML, and Solid Tumors Significant market opportunities Additional potential opportunities in current development programs with NHL expansion ABC- PCNSL FLT3m AML WM MCL MZL CLL/SLL DLBCL US Incidence per 100K 0.51 1.32 4.23 0.55 0.56 1.57 2.08 4.59 Newly Diagnosed Pe
Slide 5: Emavusertib in NHL
Emavusertib in NHL fen CUS’
Slide 6: Emavusertib's Mechanism in NHL
Emavusertib’s Mechanism in NHL BCR Pathway TLR Pathway Two pathways drive NF-ĸB B cell receptor TLR1 TLR2 TLR4 TLR5 TLR6 (which drives B-cell lymphomas) combining IRAK4i and BTKi Endosome TLR7 TLR8 TLR9 enables dual blockade of NF-ĸB ibrutinib BTK Myddosome CARD11 MYD88 MALT1 BCL10 IRAK1 IRAK4 emavu
Slide 7: Emavusertib is synergistic with BTKi in NHL
Emavusertib is synergistic with BTKi in NHL Monotherapy vs. Combination emavusertib + BTKi 1400 in NHL vehicle 1200 blocking both pathways (BCR and TLR) Mean Tumor Volume (mm3) + SEM has been shown in preclinical data to be 1000 more effective than blocking either one alone 800 ibrutinib emavusertib
Slide 8: Strategy in NHL
Strategy in NHL ❶ Demonstrate safety 31 patients1 treated in TakeAim Lymphoma Ph 1b study, acceptable safety profile established, no overlapping dose-limiting toxicity with ibrutinib ❷ Demonstrate single-agent activity Single-agent activity demonstrated, with patients remaining on study up to 4 year
Slide 9: Emavusertib safety profile in NHL
Emavusertib safety profile in NHL1 • 31 patients treated with emavusertib in 100 mg BID 200 mg BID 300 mg BID Total Ema + Ibr Ema + Ibr Ema + Ibr combination with ibrutinib in multiple NHL Grade 3+ TRAE in >1 Patient (N=6) (N=18) (N=7) (N=31) subtypes n (%) n (%) n (%) n (%) • Shown to be well toler
Slide 10: Strategy in NHL
Strategy in NHL ❶ Demonstrate safety 31 patients1 treated in TakeAim Lymphoma Ph 1b study, acceptable safety profile established, no overlapping dose-limiting toxicity with ibrutinib ❷ Demonstrate single-agent activity Single-agent activity demonstrated, with patients remaining on study up to 4 year
Slide 11: Single-agent activity demonstrated in NHL
Single-agent activity demonstrated in NHL Percent Change in Tumor Burden from Baseline Case Study in Dose Response (WM patient) (6 patients treated for ~1 year or longer) 50 mg 100 mg 2950 2850 2750 200 mg 2650 2550 2450 2350 2250 Tumor reduction 2150 Dosing increases led sustained for up to 3+ year
Slide 12: Strategy in NHL
Strategy in NHL ❶ Demonstrate safety 31 patients1 treated in TakeAim Lymphoma Ph 1b study, acceptable safety profile established, no overlapping dose-limiting toxicity with ibrutinib ❷ Demonstrate single-agent activity Single-agent activity demonstrated, with patients remaining on study up to 4 year
Slide 13: R/R PCNSL selected for 1st NHL indication
R/R PCNSL selected for 1st NHL indication PCNSL is an orphan NHL indication, where no drugs are approved in salvage-line therapy Salvage Line Study Rationale: emavusertib + blocking both TLR and BCR pathways can 1st Line 2nd Line BTKi re-sensitize tumors and may enable (ibrutinib) patients to achiev
Slide 14: Encouraging clinical data in R/R PCNSL
Encouraging clinical data in R/R PCNSL Results for patients treated with emavusertib + ibrutinib, after they have progressed on prior BTKi 10% * Tumor Reduction Duration of Treatment 0% -10% Best change in disease burden from baseline -20% -30% 6 Responses Duration of Response > 6 months -40% in 10
Slide 15: Strategy in NHL
Strategy in NHL ❶ Demonstrate safety 31 patients1 treated in TakeAim Lymphoma Ph 1b study, acceptable safety profile established, no overlapping dose-limiting toxicity with ibrutinib ❷ Demonstrate single-agent activity Single-agent activity demonstrated, with patients remaining on study up to 4 year
Slide 16: Anti-cancer activity shown across multiple NHL subtypes
Anti-cancer activity shown across multiple NHL subtypes Data presented at ASH 2023 supports emavusertib + BTKi combination in additional NHL subtypes All patients (n=19), multiple NHL subtypes No Prior BTKi Failed Prior BTKi • Heavily pre-treated patients Best % Change in Tumor Burden (1-10 prior li
Slide 17: Opportunities in additional NHL subtypes
Opportunities in additional NHL subtypes Emavusertib’s inhibition of NF-kB via IRAK4, may enable broad therapeutic potential in NHL (US only) Tumor Incidence Key Targets of Interest SOC ABC-DLBCL 2 per 100,000 ~ 6,800 patients IRAK4, MYD88, CD79, NF-kB R-CHOP PCNSL 0.5 per 100,000 ~ 1,700 patients I
Slide 18: Summary in NHL
Summary in NHL Lymphoma • Emavusertib demonstrated anti-cancer activity in R/R PCNSL • Next steps: ⁻ Work with FDA to align on a registrational development path in R/R PCNSL ⁻ Prioritize next NHL indications (after PCNSL) that could benefit from the dual-blockade of NF-ĸB (blocking the TLR pathway w
Slide 19: Emavusertib in AML
Emavusertib in AML fen CUS’
Slide 20: Emavusertib binds to IRAK4 and FLT3, blocking both TLR and FLT3 pathways
Emavusertib binds to IRAK4 and FLT3, blocking both the TLR and FLT3 pathways Emavusertib Emavusertib Kinase Interaction Map Binding Affinity FLT3 Target Kd nM IRAK4 IRAK1 12,000 IRAK2 >20,000 IRAK3 8,500 IRAK4 DYRK1A 23 25 Binds tightly to IRAK4 CLK 1, 2, 4 FLT3 WT 31 Haspin FLT3 (D835H) FLT3 (D835V
Slide 21: IRAK4-L is an independent and powerful driver of disease in AML
IRAK4-L is an independent and powerful driver of disease in AML IRAK4-L is expressed in nearly all AML patients IRAK4-L is oncogenic in AML 800 Knocking out IRAK4 IRAK4-L stops leukemic activity IRAK4-S (similar findings using CRISPR/CAS9) 600 Sum of IRAK4 variants Control 400 200 adding back IRAK4-
Slide 22: Strategy in AML
Strategy in AML ❶ Demonstrate safety 123 patients1 treated in TakeAim Leukemia Ph 1/2 study, acceptable safety profile established ❷ Demonstrate single-agent activity Single-agent activity observed; next step is to confirm these initial findings in a larger number of patients ❸ Pursue fastest path t
Slide 23: Safety Profile of Emavusertib as Monotherapy in AML
Safety Profile of Emavusertib as Monotherapy in AML 200 mg BID 300 mg BID 400 mg BID 500 mg BID Total Grade 3+ TRAE > 1 patients (n = 27) (n = 78) (n = 15) (n = 3) (n=123) • 123 patients treated with emavusertib n (%) n (%) n (%) n (%) n (%) in TakeAim Leukemia Study Number of patients having 4 (14.
Slide 24: Strategy in AML
Strategy in AML ❶ Demonstrate safety 123 patients1 treated in TakeAim Leukemia Ph 1/2 study, acceptable safety profile established ❷ Demonstrate single-agent activity Single-agent activity observed; next step is to confirm these initial findings in a larger number of patients ❸ Pursue fastest path t
Slide 25: Single-agent activity demonstrated in AML
Single-agent activity demonstrated in AML Patients treated at 300mg BID All Patients, All Dose Levels who also have FLT3 mutation 100% 100% 80% 80% 60% Before optimizing 60% 6 of 11 evaluable patients for Dose & FLT3m achieved objective response 40% 40% 20% 20% Enrich for 0% Dose & FLT3m 0% -20% -20
Slide 26: Strategy in AML
Strategy in AML ❶ Demonstrate safety 123 patients1 treated in TakeAim Leukemia Ph 1/2 study, acceptable safety profile established ❷ Demonstrate single-agent activity Single-agent activity observed; next step is to confirm these initial findings in a larger number of patients ❸ Pursue fastest path t
Slide 27: Emavusertib in FLT3m AML
Emavusertib in FLT3m AML fen CUS’
Slide 28: Emavusertib's dual-targeting of IRAK4 and FLT3 enables monotherapy opportunity in FLT3m AML
Emavusertib’s dual-targeting of IRAK4 and FLT3 enables monotherapy opportunity in FLT3m AML IRAKi synergy with FLT3i 100% – 75% – FLT3i Control IRAK4 inhibition overcomes adaptive resistance to FLT3i 50% – IRAKi 25% – Concomitant targeting of IRAK1 or IRAK4, alongside FLT3, is the most effective mea
Slide 29: Emavusertib is a potential best-in-class therapy in FLT3m AML
Emavusertib is a potential best-in-class therapy in FLT3m AML CR/CRh/CRi Rate 35% Salvage Line Patients 30% treated with emavusertib achieved > 30% CR/CRh rate 25% Benchmark ~1.5X greater than the benchmark in FLT3i-naïve patients is for FLT3i-naïve patients 20% 21% CR/CRh rate 15% 87% of patients i
Slide 30: Encouraging updated data in FLT3m AML
Encouraging updated data in FLT3m AML presented at ASCO/EHA 2024 Duration on Treatment CR CR MLFS went to SCT CR → went to SCT CRh → 6 of 11 evaluable patients ongoing achieved objective response ongoing MLFS → ongoing → ongoing → Not Evaluable Days on Treatment 0 days 50 100 150 200 250 300 Source:
Slide 31: Strategy in AML
Strategy in AML ❶ Demonstrate safety 123 patients1 treated in TakeAim Leukemia Ph 1/2 study, acceptable safety profile established ❷ Demonstrate single-agent activity Single-agent activity observed; next step is to confirm these initial findings in a larger number of patients ❸ Pursue fastest path t
Slide 32: Emavusertib in All Comers
Emavusertib in All Comers fen CUS’
Slide 33: Emavusertib combination with aza/ven targets all comers in frontline AML
Emavusertib combination with aza/ven targets all comers in frontline AML oncogenic IRAK4-L is expressed emavusertib synergy with aza/ven ema/aza/ven in nearly all AML patients in preclinical studies triplet combination 800 Preclinical Data All Comers Model Relative cell growth in AML cell lines (THP
Slide 34: Summary in AML
Summary in AML Leukemia • Emavusertib targets both FLT3 and IRAK4 • Emavusertib offers potential for best-in-class therapeutic in FLT3m AML (a genetically-defined population) • Oncogenic IRAK4 is expressed in nearly all AML patients and is not addressed by current standard-of-care (azacitidine and v
Slide 35: Solid Tumors
Solid Tumors fen CUS’
Slide 36: Ongoing studies (ISTs) of emavusertib in Solid Tumors
Ongoing studies (ISTs) of emavusertib in Solid Tumors Tumor Type Institution (Investigator) Emavusertib Combination Partner CRADA Washington University (Grierson) Pancreatic gemcitabine, (nab)-paclitaxel Washington University (Lim) CRADA Oklahoma University (Ulahannan) Colorectal FOLFOX + bevacizuma
Slide 37: Other Information
Other Information fen CUS’
Slide 38: Financials and IP
Financials and IP We believe cash is sufficient to achieve anticipated near-term milestones As of September 30, 20241 • Data in ~20 pts in R/R FLT3m AML (ASH 2024) $31.6M Cash and investments • Updated PCNSL data in ~15-20 patients (1Q25) ~8.5M Shares Outstanding • AML triplet initial safety data (1
Slide 39: End of Presentation
End of Presentation fen CUS’